Results 221 to 230 of about 3,323,629 (269)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer [PDF]
Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of ...
Matthew R. Smith +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2020
Androgen deprivation therapy (ADT) has been the standard of care for treating advanced prostate cancer for many decades. Prostate cancer cells are generally androgen-dependent, and most patients with advanced disease will respond to ADT in some form or another. Androgen deprivation therapy is utilized in the suppression of testosterone production.
Charlene Reyes +2 more
openaire +2 more sources
Androgen deprivation therapy (ADT) has been the standard of care for treating advanced prostate cancer for many decades. Prostate cancer cells are generally androgen-dependent, and most patients with advanced disease will respond to ADT in some form or another. Androgen deprivation therapy is utilized in the suppression of testosterone production.
Charlene Reyes +2 more
openaire +2 more sources
Androgen deprivation therapy complications
Endocrine-Related Cancer, 2014Androgen deprivation therapy (ADT) is increasingly used to treat advanced prostate cancer and is also utilised as adjuvant or neo-adjuvant treatment for high-risk disease. The resulting suppression of endogenous testosterone production has deleterious effects on quality of life, including hot flushes, reduced mood and cognition and diminished sexual ...
Carolyn A, Allan +4 more
openaire +2 more sources
Androgen deprivation therapy and cardiovascular disease
Urologic Oncology: Seminars and Original Investigations, 2020Prostate cancer (PCa) is the most common cancer among men. Advances in early detection and successful treatments have improved cancer-specific survival. With prolonged survival, PCa patients now suffer from the effects of aging and are at increasing risk for the development of cardiovascular (CV) risk factors and CV disease.
Chiara, Melloni, Matthew T, Roe
openaire +2 more sources
Indications and Practice With Androgen Deprivation Therapy
Urology, 2011The Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) is an ongoing longitudinal observational study of current trends in prostate cancer staging and treatment across a spectrum of different treatment facilities in the United States.
Judd W, Moul +3 more
openaire +2 more sources
Traditional Approaches to Androgen Deprivation Therapy
Urology, 2011For most of the past 25 years, 1 of the favored approaches to treating prostate cancer has been the suppression of circulating testosterone with luteinizing hormone-releasing hormone (LHRH) agonists. LHRH agonists produce a downregulation of LHRH receptors and an uncoupling of the LHRH signal transduction mechanism.
Judd W, Moul +4 more
openaire +2 more sources
Androgen deprivation therapy for prostate cancer
Expert Opinion on Pharmacotherapy, 2008Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the ...
Eric A, Singer +3 more
openaire +2 more sources
Androgen Deprivation Therapy and Competing Risks
JAMA, 2011among patients receiving ADT vs control was 11.0% (95% CI, 8.3%-14.5%) vs 11.2% (95% CI, 8.3%-15.0%), respectively, and the corresponding relative risk (RR) was not significant (0.93; 95% CI, 0.79-1.10; P=.41). The duration of ADT (long duration [3 years] vs short duration [6 months]) was not associated with increased cardiovascular death. An important
William K, Kelly, Leonard G, Gomella
openaire +2 more sources

